Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Carfilzomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Proof of concept; Therapeutic Use
- 01 Jun 2018 Planned number of patients changed from 30 to 53.
- 07 Aug 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2019.
- 07 Aug 2017 Status changed from active, no longer recruiting to recruiting.